Molecular Requirements for the Expression of Antiplatelet Effects by Synthetic Structural Optimized Analogues of the Anticancer Drugs Imatinib and Nilotinib
Despoina Pantazi,1 Nikoleta Ntemou,2 Alexios Brentas,2 Dimitrios Alivertis,3 Konstantinos Skobridis,2 Alexandros D Tselepis1 1Department of Chemistry, Atherothrombosis Research Centre, Laboratory of Biochemistry, University of Ioannina, Ioannina 45110, Greece; 2Department of Chemistry, Section of Or...
Main Authors: | Pantazi D, Ntemou N, Brentas A, Alivertis D, Skobridis K, Tselepis AD |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/molecular-requirements-for-the-expression-of-antiplatelet-effects-by-s-peer-reviewed-article-DDDT |
Similar Items
-
Antiplatelet and Antithrombotic Activity of a Traditional Medicine, Hwangryunhaedok-Tang
by: Kyungho Kim, et al.
Published: (2019-01-01) -
The Metabolites of the Dietary Flavonoid Quercetin Possess Potent Antithrombotic Activity, and Interact with Aspirin to Enhance Antiplatelet Effects
by: Alexander R. Stainer, et al.
Published: (2019-07-01) -
Synthesis and Biological Evaluation of Thio-Derivatives of 2-Hydroxy-1,4-Naphthoquinone (Lawsone) as Novel Antiplatelet Agents
by: Matías Monroy-Cárdenas, et al.
Published: (2020-08-01) -
Preclinical pharmacokinetic evaluation to facilitate repurposing of tyrosine kinase inhibitors nilotinib and imatinib as antiviral agents
by: Hari Krishna Ananthula, et al.
Published: (2018-12-01) -
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
by: Katerina Arvaniti, et al.
Published: (2014-07-01)